PharmAla Biotech Holdings Inc. (OTC:MDXXF) announced it has agreed to supply its LaNeo MDMA for a clinical trial at Harvard's Maclean Hospital, a world-leading institution in neuroscience and psychiatric research. This agreement marks a significant step for PharmAla as it continues to expand its role in supporting MDMA-based clinical research across the U.S. The company's CEO, Nicholas Kadysh, emphasized the growing interest from key research organizations and the company's commitment to delivering high-quality MDMA for clinical trials. This development comes less than a month after PharmAla was contracted to be a supplier of MDMA to a clinical trial at Johns Hopkins Medicine.

Additionally, PharmAla will be attending the CPHI conference in Milan from October 7-11, where the company aims to further discussions with potential European distribution partners. Dr. Shane Morris, COO of PharmAla, highlighted the ongoing efforts to expand their distribution network in Europe. "Over the past few months, PharmAla has been in discussion with a number of potential distribution partners in the European market," he said. "We're looking forward to the opportunity to meet with them, in-person, to continue those fruitful discussions."

Cover image made wth AI